4/30
11:59 am
bdrx
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting [Yahoo! Finance]
High
Report
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting [Yahoo! Finance]
4/30
11:51 am
bdrx
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
High
Report
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
4/26
08:41 am
bdrx
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) [Yahoo! Finance]
High
Report
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) [Yahoo! Finance]
4/26
08:30 am
bdrx
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
High
Report
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
4/19
08:19 am
bdrx
Preliminary Results for the Year Ended 31 December 2023 [Yahoo! Finance]
Medium
Report
Preliminary Results for the Year Ended 31 December 2023 [Yahoo! Finance]
4/19
08:00 am
bdrx
Preliminary Results for the Year Ended 31 December 2023
Medium
Report
Preliminary Results for the Year Ended 31 December 2023
3/28
08:28 am
bdrx
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers [Yahoo! Finance]
High
Report
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers [Yahoo! Finance]
3/28
08:15 am
bdrx
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
High
Report
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
3/1
08:19 am
bdrx
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone [Yahoo! Finance]
Low
Report
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone [Yahoo! Finance]
3/1
08:00 am
bdrx
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
Medium
Report
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
2/23
08:34 am
bdrx
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update [Yahoo! Finance]
High
Report
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update [Yahoo! Finance]
2/23
08:30 am
bdrx
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
Medium
Report
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
2/16
01:15 pm
bdrx
Global Somatostatin Analogs Market Report 2024-2030 Featuring Major Players - Novartis, Sun Pharma, Midatech Pharma, Ipsen Pharma, Chiasma, Peptron, Dauntless Pharma, Camurus, Teva, and Pfizer
Low
Report
Global Somatostatin Analogs Market Report 2024-2030 Featuring Major Players - Novartis, Sun Pharma, Midatech Pharma, Ipsen Pharma, Chiasma, Peptron, Dauntless Pharma, Camurus, Teva, and Pfizer
2/14
11:32 am
bdrx
Global Modified Release Neurology Therapeutics Analysis 2024 - Extended Release Formulations Redefine Treatment Protocols [Yahoo! Finance]
Low
Report
Global Modified Release Neurology Therapeutics Analysis 2024 - Extended Release Formulations Redefine Treatment Protocols [Yahoo! Finance]
2/14
11:15 am
bdrx
Global Modified Release Neurology Therapeutics Analysis 2024 - Extended Release Formulations Redefine Treatment Protocols
Low
Report
Global Modified Release Neurology Therapeutics Analysis 2024 - Extended Release Formulations Redefine Treatment Protocols
2/8
08:51 am
bdrx
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients [Yahoo! Finance]
Medium
Report
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients [Yahoo! Finance]
2/8
08:30 am
bdrx
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
High
Report
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
2/8
07:40 am
bdrx
Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $8.00 price target on the stock.
Medium
Report
Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $8.00 price target on the stock.
2/7
08:43 am
bdrx
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone [Yahoo! Finance]
High
Report
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone [Yahoo! Finance]
2/7
08:30 am
bdrx
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
High
Report
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone